Comparative Analysis of Legislative Requirements About Patients’ Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries
ORIGINAL RESEARCH published: 20 July 2018 doi: 10.3389/fphar.2018.00795 Comparative Analysis of Legislative Requirements About Patients’ Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries Maria Kamusheva 1*, Manoela Manova 1,2, Alexandra T. Savova 1,2, Guenka I. Petrova 1, Konstantin Mitov 1, András Harsányi 3,4, Zoltán Kaló 3,5, Kristóf Márky 4, Pawel Kawalec 6, Bistra Angelovska 7, Dragana Lakic´ 8, Tomas Tesar 9, Pero Draganic 10, Mary Geitona 11, Magdalini Hatzikou 11, Marian S. Paveliu 12 and Agnes Männik 13 Edited by: 1 Iñaki Gutiérrez-Ibarluzea, Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University-Sofia, Sofia, Bulgaria, 2 3 Basque Office for Health Technology National Council on Pricing and Reimbursement, Sofia, Bulgaria, Department of Health Policy and Health Economics, 4 Assessment, Osteba, Spain Eötvös Loránd University, Budapest, Hungary, National Institute of Health Insurance Fund Management, Budapest, Hungary, 5 Syreon Research Institute, Budapest, Hungary, 6 Faculty of Health Sciences, Institute of Public Health, Jagiellonian Reviewed by: University Medical College Kraków, Kraków, Poland, 7 Department of Pharmacy, Faculty of Medical Sciences, University Goce Kurt Neumann, Delcev- Stip, Štip, Macedonia, 8 Department for Social Pharmacy and Pharmaceutical Legislation, Faculty of Pharmacy, Independent Researcher, Kerékteleki, University of Belgrade, Belgrade, Serbia, 9 Department of Organization and Management in Pharmacy, Faculty of Pharmacy, Hungary
[Show full text]